Annovis Bio (ANVS) Competitors $2.02 -0.12 (-5.51%) Closing price 03:59 PM EasternExtended Trading$2.02 -0.01 (-0.35%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. CRBP, LXEO, VTYX, ANIX, SNTI, ZURA, CLLS, CLYM, IZTC, and OCXShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include Corbus Pharmaceuticals (CRBP), Lexeo Therapeutics (LXEO), Ventyx Biosciences (VTYX), Anixa Biosciences (ANIX), Senti Biosciences (SNTI), Zura Bio (ZURA), Cellectis (CLLS), Climb Bio (CLYM), Invizyne Technologies (IZTC), and OncoCyte (OCX). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Corbus Pharmaceuticals Lexeo Therapeutics Ventyx Biosciences Anixa Biosciences Senti Biosciences Zura Bio Cellectis Climb Bio Invizyne Technologies OncoCyte Corbus Pharmaceuticals (NASDAQ:CRBP) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership, valuation and community ranking. Does the media refer more to CRBP or ANVS? In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than Annovis Bio. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 5 mentions for Annovis Bio. Corbus Pharmaceuticals' average media sentiment score of 1.15 beat Annovis Bio's score of -0.17 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of CRBP or ANVS? 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 3.6% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 20.8% of Annovis Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, CRBP or ANVS? Corbus Pharmaceuticals has a beta of 3.19, suggesting that its stock price is 219% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Do analysts rate CRBP or ANVS? Corbus Pharmaceuticals presently has a consensus price target of $50.88, suggesting a potential upside of 586.57%. Annovis Bio has a consensus price target of $34.75, suggesting a potential upside of 1,618.60%. Given Annovis Bio's higher probable upside, analysts plainly believe Annovis Bio is more favorable than Corbus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corbus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has preferable valuation & earnings, CRBP or ANVS? Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorbus PharmaceuticalsN/AN/A-$44.60M-$4.22-1.76Annovis BioN/AN/A-$56.20M-$2.16-0.94 Does the MarketBeat Community favor CRBP or ANVS? Corbus Pharmaceuticals received 428 more outperform votes than Annovis Bio when rated by MarketBeat users. However, 93.94% of users gave Annovis Bio an outperform vote while only 67.20% of users gave Corbus Pharmaceuticals an outperform vote. CompanyUnderperformOutperformCorbus PharmaceuticalsOutperform Votes45967.20% Underperform Votes22432.80% Annovis BioOutperform Votes3193.94% Underperform Votes26.06% Is CRBP or ANVS more profitable? Annovis Bio's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Corbus PharmaceuticalsN/A -42.28% -32.92% Annovis Bio N/A N/A -311.00% SummaryCorbus Pharmaceuticals beats Annovis Bio on 9 of the 15 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$28.79M$6.48B$5.35B$19.37BDividend YieldN/A2.66%5.22%3.84%P/E Ratio-0.458.9226.8434.23Price / SalesN/A250.96391.3934.85Price / CashN/A65.8538.2517.51Price / Book-2.776.466.794.69Net Income-$56.20M$143.98M$3.23B$1.02B7 Day Performance18.59%3.04%4.07%-1.34%1 Month Performance48.68%7.44%12.52%9.79%1 Year Performance-75.43%-2.46%16.83%3.27% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio2.0772 of 5 stars$2.02-5.5%$34.75+1,618.6%-76.2%$28.79MN/A-0.453Gap DownCRBPCorbus Pharmaceuticals4.588 of 5 stars$7.16+11.0%$50.88+610.5%-84.4%$87.58MN/A-1.5340Positive NewsLXEOLexeo Therapeutics2.8592 of 5 stars$2.63-2.2%$22.20+744.1%-74.4%$87.31M$650,000.00-0.8358News CoverageAnalyst RevisionGap DownHigh Trading VolumeVTYXVentyx Biosciences2.1512 of 5 stars$1.21-2.4%$10.00+726.4%-67.1%$86.11MN/A-0.5130News CoveragePositive NewsGap UpANIXAnixa Biosciences1.7313 of 5 stars$2.66+1.9%$9.00+238.3%-8.1%$85.64M$210,000.00-6.825Gap UpSNTISenti Biosciences1.696 of 5 stars$3.26flat$12.00+268.1%-14.9%$85.02M$2.56M-0.214ZURAZura Bio2.8762 of 5 stars$1.24+2.5%$14.33+1,055.9%-82.1%$84.79MN/A-2.343News CoverageAnalyst RevisionCLLSCellectis2.9116 of 5 stars$1.51-4.4%$7.00+363.6%-48.1%$83.93M$41.51M-1.16290CLYMClimb Bio2.5919 of 5 stars$1.24+4.2%$10.00+706.5%N/A$83.79MN/A-0.589News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpIZTCInvizyne TechnologiesN/A$13.01+4.0%N/AN/A$81.34MN/A0.00N/AOCXOncoCyte2.3645 of 5 stars$2.81-2.1%$4.42+57.2%+6.5%$80.36M$1.88M-0.64120Analyst ForecastGap Down Related Companies and Tools Related Companies Corbus Pharmaceuticals Competitors Lexeo Therapeutics Competitors Ventyx Biosciences Competitors Anixa Biosciences Competitors Senti Biosciences Competitors Zura Bio Competitors Cellectis Competitors Climb Bio Competitors Invizyne Technologies Competitors OncoCyte Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ANVS Stock Free ANVS Stock Alerts